imatinib has been researched along with dabigatran in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dreger, M; Fischer, JJ; Glinski, M; Graebner, OY; Koester, H; Kroll, F; Marais, A; Metternich, R; Michaelis, S; Schaudt, C; Schrey, AK; Sefkow, M | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
2 other study(ies) available for imatinib and dabigatran
| Article | Year |
|---|---|
Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Enzyme Inhibitors; Hep G2 Cells; Humans; K562 Cells; Mass Spectrometry; Models, Chemical; Protein Binding; Proteomics; Pyridines; Quinone Reductases; Thrombin | 2012 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |